Showing 6,005 results

Filters Content type: News, Editors' picks, About HIV Topic: HIV treatment

Treatment is recommended for all people living with HIV. It involves taking a combination of antiretroviral drugs. This stops the virus from replicating and allows the immune system to strengthen and fight infections.

PrEP science

Kidney Toxicity Rare With Daily or On-Demand (As-Needed) PrEP

Editor's pick
NATAP
31 October 2021
New & experimental HIV treatments

Merck's HIV program closer to regulator's doorstep with two phase 3 trials showing efficacy comparable to existing meds

Editor's pick
FierceBiotech
31 October 2021
HIV treatment for children & young people

WHO Updates Pediatric Dosing Tool for Antiretroviral Medicines

Editor's pick
Medscape (requires free registration)
31 October 2021
Side effects

Large international study finds 40% higher risk of serious cardiovascular problems in people taking abacavir since 2012

News
28 October 2021
Resistance

New cases of multi-drug resistant HIV becoming rarer in Europe

News
28 October 2021
Injectable & long-acting HIV treatment

ViiV Healthcare announces European Commission Decision for Vocabria (cabotegravir) and Rekambys (rilpivirine) injections to be initiated with or without an oral lead-in period for the long-acting treatment of HIV

Editor's pick
ViiV Healthcare
28 October 2021
Low & theoretical transmission risks

Fact Check - Transmission of HIV by needle injuries is highly unlikely, according to a British AIDS charity

Editor's pick
Reuters
27 October 2021
Bad science & bogus treatments

Facebook, YouTube Take Down Bolsonaro Video That Said Vaccines Cause AIDS

Editor's pick
The Wire
26 October 2021
Injectable & long-acting HIV treatment

Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults

Editor's pick
Gilead press release
26 October 2021
Sexually transmitted infections epidemiology

Should we be worried about donovanosis, a rare, so-called 'flesh-eating' STI?

Editor's pick
The Washington Post
26 October 2021
New & experimental HIV treatments

Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection

Editor's pick
Merck press release
25 October 2021
PrEP science

What are the side effects of Truvada used for PrEP?

About HIV
October 2021
Cardiovascular disease

Large US study confirms that people switching from TDF to TAF experience rising blood fat levels

News
15 October 2021
Improving HIV care

Working together to improve HIV care in Europe

News
14 October 2021
Liver disease

People with HIV taking newer antiretrovirals at higher risk of fatty liver disease

News
12 October 2021
Injectable & long-acting HIV treatment

Cabotegravir (Vocabria®) is accepted for use within NHSScotland

Editor's pick
Scottish Medicines Consortium
11 October 2021
Treatment outcomes & life expectancy

US: Black Women With HIV Die Earlier Than Their White Female or Black Male Peers

Editor's pick
POZ
11 October 2021
HIV treatment

What is an elite controller?

About HIV
October 2021
PrEP science

Islatravir Subdermal Implant for HIV PrEP Has Promising Phase 1 Trial

Editor's pick
Contagion Live
7 October 2021
Weight gain & lipodystrophy

Older version of tenofovir used as PrEP linked to weight loss

News
5 October 2021
People & personal stories

Fit at 50: gaining weight at midlife isn’t inevitable

Editor's pick
POZ
4 October 2021
Treatment outcomes & life expectancy

US: Among people with HIV, Black women have highest rate of premature death

Editor's pick
Healio
4 October 2021
Sleep

Sleep and HIV

About HIV
October 2021
PrEP science

Most switches to Descovy PrEP are probably unnecessary and some may be harmful

News
1 October 2021